Cardiothoracic & vascular anesthesia
Recombinant Activated Factor VII (rFVIIa) for Bleeding After Thoracic Aortic Surgery: A Scoping Review of Current Literature
Authors' conclusion
Limited evidence suggests that rFVIIa may be useful in managing postoperative refractory bleeding in patients undergoing thoracic aortic surgery. However, the impact of rFVIIa on thromboembolic complications and mortality rates remains unclear.
Study context
- Population
- Patients undergoing surgical repair of ascending or descending aortic aneurysm or dissection with refractory postoperative bleeding10 publications
- Participants
- 649 patients
- Comparison
- rFVIIa vs control
- rFVIIan = 319
- Controln = 330reference
- Outcome
- Coagulopathy and postoperative blood loss
Methodological detailsMedline, Embase, Cochrane Library and Google Scholar searched in June 2023; single-case reports excluded
- Medline, Embase, Cochrane Library and Google Scholar searched in June 2023; single-case reports excluded
Main finding
As reported in the abstract
- All studies reported a potential role of rFVIIa in correcting coagulopathy and reducing postoperative blood loss
- 3 case series, 6 retrospective studies, 1 nonrandomized clinical trial
Further findings
- Not enough evidence that rFVIIa was associated with higher rates of thromboembolic complications or mortality
Original publication
Recombinant Activated Factor VII (rFVIIa) for Bleeding After Thoracic Aortic Surgery: A Scoping Review of Current Literature. J Cardiothorac Vasc Anesth. Published 27 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →